Coalition for Epidemic Preparedness Innovations & Gilead Sciences

Coalition for Epidemic Preparedness Innovations: The Coalition for Epidemic Preparedness Innovations (CEPI) is funding three groups, including Moderna and the University of Oxford, to accelerate the development of vaccines against the Bundibugyo strain of Ebola.

Gilead Sciences: Gilead Sciences' experimental oral COVID antiviral drug, Obeldesivir, is being considered for use as a preventative treatment for Ebola contacts, under strict protocol.

Coalition for Epidemic Preparedness Innovations: The Coalition for Epidemic Preparedness Innovations (CEPI) funds vaccine development and is assessing potential Ebola vaccine candidates, aiming for a rapid response.

Gilead Sciences: Gilead Sciences' antiviral drug remdesivir and experimental drug obeldesivir are being prioritized for clinical trials to treat or prevent the Bundibugyo ebolavirus, indicating its significant role in potential therapies.

Coalition for Epidemic Preparedness Innovations: CEPI is listed as a partner in the urgent coordination meeting convened by Africa CDC, indicating potential involvement in the response to the Ebola outbreak.

Gilead Sciences: Gilead Sciences is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Coalition for Epidemic Preparedness Innovations: Partner in vaccine development efforts.

Gilead Sciences: Supplying remdesivir for clinical trials; potential positive impact if treatment proves effective.